Promotional price valid on web orders only. Your contract pricing may differ. Interested in signing up for a dedicated account number?
Learn More
Learn More
R&D Systems™ Recombinant Human IL-39 Fc Chimera Protein
Extensive quality control produces industry leading bioactivity and lot-to-lot consistency that instills confidence in results and ensures reproducibility.
Applications: Bioactivity
Supplier: R&D Systems™ 9990IL050
This item is not returnable.
View return policy
Description
The Recombinant Human IL-39 Fc Chimera Protein is derived from HEK293. The Recombinant Human IL-39 Fc Chimera Protein has been validated for the following applications: Bioactivity.Specifications
Q14213, Q9NPF7 | |
69 kDa | |
Human embryonic kidney cell,HEK293-derived human IL-39 (IL-23p19/EBI3) protein Human EBI3 (Arg21-Lys229,Gln95Cys) Accession &Num; Q14213 GGGSGGGSGGGS Human IL-23p19 (Arg20-Pro189) Accession &Num; Q9NPF7 IEGRMD Human IgG1 (Pro100-Lys330) | |
RUO | |
IL-39 (IL-23p19/EBI3) | |
Human | |
Reconstitute at 200 μg/mL in PBS. | |
>90%, by SDS-PAGE visualized with Silver Staining and quantitative densitometry by Coomassie« Blue Staining. |
Bioactivity | |
50 μg | |
12 months from date of receipt, <= -20 °C as supplied. 1 month, 2 to 8 °C under sterile conditions after reconstitution. 3 months, <= -20 °C under sterile conditions after reconstitution. | |
<0.10 EU per 1 μg of the protein by the LAL method. | |
Unconjugated | |
Recombinant | |
Lyophilized from a 0.2 μm filtered solution in PBS with Trehalose. |
Provide Content Correction
We continue to work to improve your shopping experience and your feedback regarding this content is very important to us. Please use the form below to provide feedback related to the content on this product.
Product Title
Spot an opportunity for improvement?
Provide Content Correction